Medisun launched the “Hong Kong Regenerative Medisun Association”

Medisun launched the “Hong Kong Regenerative Medisun Association”

On May 28, 2018, the Hong Kong Regenerative Medisun Association, which was initiated by representatives from the Hong Kong Regenerative Medisun Industry and academic circles, was formally established under the auspices of the Medisun Medical Group.

Hong Kong Regenerative Medisun Association goals

The Hong Kong Regenerative Medisun Association was founded by experts, scholars, industry representatives and people of insight in the field of regenerative Medisun in Hong Kong and around the world. The purpose of the association is to establish a consensus platform for the regenerative Medisun industry in Hong Kong, promote the development of the regenerative Medisun industry, encourage and promote international cooperation, and propose to the Hong Kong SAR government the recommendations of the regenerative Medisun industry on industry regulations and actively influence industry rules. The establishment and improvement of the company provides effective technical and management advice to the Hong Kong government, Hong Kong public health agencies and companies in the industry.

The first meeting of the Hong Kong Regenerative Medisun Association (May 28, 2018)

On the afternoon of May 28, representatives from Hong Kong’s medical health, regenerative Medisun and biotechnology fields, doctors, pharmacists, chemists and university researchers gathered to discuss and elect the first council of the Hong Kong Regenerative Medisun Association.They read the charter of the association and clarify the duties of the board. At the same time, they have had a heated discussion on the regulatory documents issued by the Hong Kong SAR Government on Advanced Therapy Products. They agreed to regulate the direction of document guidance and proposed a number of issues that need to be clarified, including:

1. Professional qualifications required by the licensee of the Regenerative Medisun and Stem Cell Research and Development Organization;

2. Advanced Therapy Products is regulated by the Pharmacy and Poisons Ordinance (Cap. 138). However, since the production process and user definition of cellular products and pharmaceutical products are different, they should be clarified accordingly;

3. With reference to the requirements of the international GMP/PICS standard, which standard should be achieved in the cell laboratory qualification of existing regenerative Medisun institutions;

4. After the specific regulation is in force, whether there should be a transition period, so that the industry has time to adjust and cooperate;

5. Submit the Advanced Therapy Products comments and submit them to the Hong Kong Department of Health.

Member of the First Council of the Hong Kong Regenerative Medisun Association

Position

Name

 Qualifications

Chairman

Danny Wong Mr. Wang Xiaofeng

 Founder and Chairman of Medisun Medical Group, years of investment experience in the field of regenerative Medisun, understanding the development and trends of the biotechnology industry

Vice President

Joseph Wang  Dr. Wang Qiyuan

Registered as a doctor, founder of the Hong Kong Stem Cell Center, enriching the clinical experience of regenerative Medisun

Vice President

David Leung Mr. Liang Yaoming

Registered pharmacist, familiar with pharmaceutical regulations and GMP requirements

Vice Chairman

Gregory Cheng Professor Zheng Yanming

Hematology expert, Professor of the University of Macau Health Sciences

Director | Treasurer

Kenneth Lee Dr. Li Zhisheng

Registered as a doctor, B Q Anti-aging Center Consultant

Director

Philip Choy Dr. Cai Shaolong

Ph.D. in Natural Medisun, Madison Biomedical Director

Director

Daniel Tam Dr. Tan Yizhu

Registered as a medical laboratory technologist, director of the Trans-Olympic Blood Bank Laboratory, focusing on cell culture technology for many years

Director

Vivien Leung Ms. Liang Yiqun

 Registered as a medical laboratory technologist, manager of the Trans-Olympic Blood Bank Laboratory, familiar with quality management

Director

Chris Wong Dr. Huang Libao

 Registered as a medical laboratory technologist, director of HKMDPC, molecular biodiagnostic expert

Secretary

Sidney Tam Dr. Tan Guozhen

Chief Executive Officer, Life Clinic, Health Management Consultant

Secretary

Allen Chan Mr. Chen Yuxin

Registered as a medical laboratory technologist, familiar with quality management

The first meeting of the Hong Kong Regenerative Medisun Association (May 28, 2018)

Hong Kong Regenerative Medisun Association’s recent work plan

Next, the Hong Kong Regenerative Medisun Association will issue letters to the organizations including the Hong Kong Department of Health, the Hong Kong Stock Exchange, the Hong Kong University Biomedical Science, Life Sciences, and the Global Regenerative Medisun Alliance (ARM). include:

1. Announced the official establishment of the Hong Kong Regenerative Medisun Association

2. Announce the initial membership list of the Hong Kong Regenerative Medisun Council, association charter, association vision and goals

3. Call for the support and participation of experts, scholars and industry representatives from Hong Kong and around the world

4. Propose to the Hong Kong Government to clarify regulatory regulations on Advanced Medisun and Advanced Therapy Products

Special thanks

Thank you for taking the time to attend the representatives of the institutions, including:

Medisun Medical Group | Medisun Reproductive Medisun Center

Hong Kong Life Science and Technology Group Co., Ltd.

Standard Pathology Laboratory Co., Ltd.

BIH

Living Tissues company limited

BIB Health Care Centre

Hongxin Medical Center

Austa beauty

Hong Kong International Regenerative Medisun Centre

HKMPDC

Huixin Technology

Guangzhou Biological Institute

Trans-along cord blood bank

Hong Kong Stem Cell Center

Life Length

Biocell

Cordlife

For more information, please visit http://www.medisun.hk/

Medisun launched the “Hong Kong Regenerative Medisun Association”

Medisun launched the “Hong Kong Regenerative Medisun Association”

On May 28, 2018, the Hong Kong Regenerative Medisun Association, which was initiated by representatives from the Hong Kong Regenerative Medisun Industry and academic circles, was formally established under the auspices of the Medisun Medical Group.

Hong Kong Regenerative Medisun Association goals

The Hong Kong Regenerative Medisun Association was founded by experts, scholars, industry representatives and people of insight in the field of regenerative Medisun in Hong Kong and around the world. The purpose of the association is to establish a consensus platform for the regenerative Medisun industry in Hong Kong, promote the development of the regenerative Medisun industry, encourage and promote international cooperation, and propose to the Hong Kong SAR government the recommendations of the regenerative Medisun industry on industry regulations and actively influence industry rules. The establishment and improvement of the company provides effective technical and management advice to the Hong Kong government, Hong Kong public health agencies and companies in the industry.

The first meeting of the Hong Kong Regenerative Medisun Association (May 28, 2018)

On the afternoon of May 28, representatives from Hong Kong’s medical health, regenerative Medisun and biotechnology fields, doctors, pharmacists, chemists and university researchers gathered to discuss and elect the first council of the Hong Kong Regenerative Medisun Association.They read the charter of the association and clarify the duties of the board. At the same time, they have had a heated discussion on the regulatory documents issued by the Hong Kong SAR Government on Advanced Therapy Products. They agreed to regulate the direction of document guidance and proposed a number of issues that need to be clarified, including:

1. Professional qualifications required by the licensee of the Regenerative Medisun and Stem Cell Research and Development Organization;

2. Advanced Therapy Products is regulated by the Pharmacy and Poisons Ordinance (Cap. 138). However, since the production process and user definition of cellular products and pharmaceutical products are different, they should be clarified accordingly;

3. With reference to the requirements of the international GMP/PICS standard, which standard should be achieved in the cell laboratory qualification of existing regenerative Medisun institutions;

4. After the specific regulation is in force, whether there should be a transition period, so that the industry has time to adjust and cooperate;

5. Submit the Advanced Therapy Products comments and submit them to the Hong Kong Department of Health.

Member of the First Council of the Hong Kong Regenerative Medisun Association

Position

Name

 Qualifications

Chairman

Danny Wong Mr. Wang Xiaofeng

 Founder and Chairman of Medisun Medical Group, years of investment experience in the field of regenerative Medisun, understanding the development and trends of the biotechnology industry

Vice President

Joseph Wang  Dr. Wang Qiyuan

Registered as a doctor, founder of the Hong Kong Stem Cell Center, enriching the clinical experience of regenerative Medisun

Vice President

David Leung Mr. Liang Yaoming

Registered pharmacist, familiar with pharmaceutical regulations and GMP requirements

Vice Chairman

Gregory Cheng Professor Zheng Yanming

Hematology expert, Professor of the University of Macau Health Sciences

Director | Treasurer

Kenneth Lee Dr. Li Zhisheng

Registered as a doctor, B Q Anti-aging Center Consultant

Director

Philip Choy Dr. Cai Shaolong

Ph.D. in Natural Medisun, Madison Biomedical Director

Director

Daniel Tam Dr. Tan Yizhu

Registered as a medical laboratory technologist, director of the Trans-Olympic Blood Bank Laboratory, focusing on cell culture technology for many years

Director

Vivien Leung Ms. Liang Yiqun

 Registered as a medical laboratory technologist, manager of the Trans-Olympic Blood Bank Laboratory, familiar with quality management

Director

Chris Wong Dr. Huang Libao

 Registered as a medical laboratory technologist, director of HKMDPC, molecular biodiagnostic expert

Secretary

Sidney Tam Dr. Tan Guozhen

Chief Executive Officer, Life Clinic, Health Management Consultant

Secretary

Allen Chan Mr. Chen Yuxin

Registered as a medical laboratory technologist, familiar with quality management

The first meeting of the Hong Kong Regenerative Medisun Association (May 28, 2018)

Hong Kong Regenerative Medisun Association’s recent work plan

Next, the Hong Kong Regenerative Medisun Association will issue letters to the organizations including the Hong Kong Department of Health, the Hong Kong Stock Exchange, the Hong Kong University Biomedical Science, Life Sciences, and the Global Regenerative Medisun Alliance (ARM). include:

1. Announced the official establishment of the Hong Kong Regenerative Medisun Association

2. Announce the initial membership list of the Hong Kong Regenerative Medisun Council, association charter, association vision and goals

3. Call for the support and participation of experts, scholars and industry representatives from Hong Kong and around the world

4. Propose to the Hong Kong Government to clarify regulatory regulations on Advanced Medisun and Advanced Therapy Products

Special thanks

Thank you for taking the time to attend the representatives of the institutions, including:

Medisun Medical Group | Medisun Reproductive Medisun Center

Hong Kong Life Science and Technology Group Co., Ltd.

Standard Pathology Laboratory Co., Ltd.

BIH

Living Tissues company limited

BIB Health Care Centre

Hongxin Medical Center

Austa beauty

Hong Kong International Regenerative Medisun Centre

HKMPDC

Huixin Technology

Guangzhou Biological Institute

Trans-along cord blood bank

Hong Kong Stem Cell Center

Life Length

Biocell

Cordlife

For more information, please visit http://www.medisun.hk/

Dubailand – Premiere Property Investment Location

Dubailand is the vision of Dubai’s current ruler Sheikh Mohammed bin Rashid Al Maktoum. The development is expected to be a full featured city divided into six theme worlds. The short range goal of Dubailand is to attract 15 million tourists to Dubai by 2020. Developers expect to accomplish this goal by creating a tourism, entertainment, and leisure destination that will attract visitors not only from surrounding countries but also from Europe and Asia. On a longer term basis Dubailand is seen as a way to phase out Dubai’s dependence on oil revenues by establishing a sustainable economy through higher value added services. The venture is expected to attract approximately 200,000 visitors daily and cost $20 billion dollars. The Dubailand project was officially announced on October 23rd, 2003. Dubailand will be built on a 3 billion square foot (278 km˛/107 mile˛) site and will include 45 mega projects and 200 sub projects. It will be three times the size of Walt Disney World Resort, currently the largest collection of amusement parks in the world. Private reaction towards the project has been positive and Dubai has exceeded the $4.9 billion private investment figure it expected on the entire project by collecting approximately $6 billion from the private sector for the first phase alone. Continue reading “Dubailand – Premiere Property Investment Location”